Donate
Global Diabetes Advocates Urge Novo Nordisk’s New CEO to Prioritize People Over Profits

Global Diabetes Advocates Urge Novo Nordisk’s New CEO to Prioritize People Over Profits

Facebook Google LinkedIn Twitter

Today, T1International and a coalition of global diabetes advocates released an open letter to the incoming CEO of Novo Nordisk, Maziar Mike Doustdar, urging the company to use this leadership transition as a turning point for people living with diabetes worldwide.

The letter, signed by organizations and individuals from across the globe, demands that Novo Nordisk, the largest insulin manufacturer in the world, adopt concrete, accountable policies that uphold the human right to health and ensure insulin is accessible to everyone who needs it.

“Insulin is not a luxury. For those of us living with insulin-dependent diabetes, it is as essential as oxygen,” states the letter, signed by over 500 organizations and #insulin4all advocates. “As the world’s leading producer of insulin, Novo Nordisk holds a profound responsibility.”

Three pharmaceutical companies, Novo Nordisk, Eli Lilly, and Sanofi, control over 90% of the global insulin market. For decades, their pricing strategies, product discontinuations, and lack of transparency have made it difficult or impossible for many people around the world to access the insulin they need to survive.

Two-thirds of people living with type 1 diabetes reported having difficulty accessing insulin in a 2024 survey. In low- and middle-income countries, families often spend up to two-thirds of their income on insulin and blood glucose monitoring supplies.

Novo Nordisk has publicly committed to respecting human rights. But real accountability is still missing.

Advocates are calling on the company’s new CEO to make good on these commitments by acting on four urgent priorities:

  1. Prioritize access: Guarantee affordable, uninterrupted access to all Novo Nordisk insulin products globally, especially in low-resource and high-need settings.
  2. Commit to fair practices: Ensure transparent pricing, and implement a robust plan when discontinuing any insulin product, including technology transfer and risk assessments.
  3. Lead with integrity: Align public messaging with real-world impact, stop performative branding, and support fair access in all policy and lobbying efforts.
  4. Engage meaningfully: Open direct, ongoing dialogue with the diabetes community, especially those most impacted by lack of access and affordability.

“Novo Nordisk has the power, and therefore the responsibility, to model ethical leadership in global health,” said Shaina Kasper, Executive Director at T1International. “This leadership transition is an opportunity to redefine Novo Nordisk’s legacy and center people over profits.”


If patients are facing an urgent need to access insulin, please see our insulin access and affordability resource.

Related posts:

T1International statement regarding largest cuts to healthcare coverage in American History.

T1International statement regarding largest cuts to healthcare coverage in American History.

The recently passed “One Big Beautiful Bill” represents the largest and greatest healthcare loss in American history, cutting health care for 17 million people living in this country. This bill, passed in the United States Congress today, is a profound and deadly cut for people living with diabetes, their families, and marginalized and disabled people across the country.
Read more

Findings from T1International's 2024 Out-of-Pocket Expenses and Rationing Survey

Findings from T1International's 2024 Out-of-Pocket Expenses and Rationing Survey

Read more

Make it Right: The Fight for Insulin Access on World Diabetes Day

Make it Right: The Fight for Insulin Access on World Diabetes Day

On World Diabetes Day, we shine a spotlight on a glaring injustice: millions of people with diabetes in low- and middle-income countries are denied access to affordable insulin pens—a delivery method that could save and transform lives. Pharmaceutical giants Eli Lilly, Novo Nordisk, and Sanofi have monopolized the diabetes market, prioritizing profit over people. It’s time to demand change. It’s time to make it right. Read more

Opinion: The insulin crisis is far from over

Opinion: The insulin crisis is far from over

This blog post was first published in the Hartford Courant on September 15, 2024 by Arden Parrish under the title: Opinion: The insulin crisis is far from over. Public pharma could be the solution. Read more

World Health Organization and Novo Nordisk Foundation - A Conflict of Interest

World Health Organization and Novo Nordisk Foundation - A Conflict of Interest

T1International and other organisations shared a letter today with Dr. Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization, urging that the World Health Organization reject any funding directly or indirectly from the pharmaceutical industry. The entity already rejects funding from the tobacco and formula milk industry. The letter also asks WHO to push the pharmaceutical industry to lower prices and create sustainable solutions, and to practise more transparency and accountability to the global community that the entity exists to serve. Read more

Levemir Discontinuation Impacts Patients

Levemir Discontinuation Impacts Patients

Only eight days of National Diabetes Awareness Month had passed this November when pharmaceutical company Novo Nordisk announced it would be pulling Levemir, a long-acting insulin that millions of insulin-dependent diabetic patients depend on, from the U.S. market. Read more